FinancialContent is the trusted provider of stock market information to the media industry.
April 24, 2012 at 19:08 PM EDT
TheStreet Predicts NeuVax Failure
TheStreet expects Galena Biopharma Inc.'s (Nasdaq: GALE) breast cancer vaccine NeuVax to fail its Phase III clinical trial. The stock price plummeted 34 cents to close at $1.25.
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here